Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "AiMeD"

336 News Found

Avista Therapeutics unveils AI-powered expansion of gene therapy platform
R&D | January 14, 2026

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design


Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery
R&D | January 14, 2026

Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery

Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target


AbbVie strikes deal with Trump administration on drug prices, US investment
News | January 13, 2026

AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing


MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
Clinical Trials | January 12, 2026

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms


Novartis to open Florida radioligand facility
News | January 12, 2026

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US


Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
News | January 11, 2026

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


Revvity and Lilly partner to accelerate AI drug discovery models
Digitisation | January 10, 2026

Revvity and Lilly partner to accelerate AI drug discovery models

Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering